• Publications
  • Influence
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
TLDR
Results of this trial suggest a benefit for EGFR/HER1 blockade with erlotinib in patients with HCC manifested by disease control. Expand
The Hsp90 chaperone complex as a novel target for cancer therapy.
TLDR
Early results from phase I studies indicate that 17-AAG administration results in an acceptable toxicity profile while achieving in vivo disruption of client proteins, and future directions for combinations of traditional antineoplastics with 17- AAG are discussed. Expand
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
TLDR
This study establishes the dose for future testing on this schedule and provides the first evidence of successful inhibition of FT in the clinical setting and the first hint of clinical activity for this class of agents. Expand
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
TLDR
Pazopanib seems to represent a promising therapeutic option for patients with advanced differentiated thyroid cancers, and the correlation of the patient's response and pazobanib concentration during the first cycle might indicate that treatment can be individualised to achieve optimum outcomes. Expand
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
TLDR
Combination chemotherapy with bevacizumab and erlotinib showed clinical activity with infrequent grade 3 and 4 adverse effects in patients with advanced biliary cancers, and on the basis of preliminary molecular analysis, presence of a k-ras mutation may alter erlot inib efficacy. Expand
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
TLDR
Temsirolimus was generally well tolerated on this intermittent schedule and encouraging preliminary antitumor activity was observed, and Immunologic studies did not show any consistent trend toward immunosuppression. Expand
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
TLDR
BMS-554417 is a member of a novel class of IGF-IR/insulin receptor inhibitors that have potential clinical applications because of their antiproliferative and proapoptotic activity in vitro and in vivo. Expand
Molecular markers in male breast carcinoma
TLDR
Assessment of the degree of expression and prognostic value of estrogen receptors (ER), progesterone receptors (PR), androgen receptors (AR), bcl‐2, p53, HER‐2/neu, cyclin D1, and MIB‐1 in a cohort of male breast carcinoma patients. Expand
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
TLDR
The data suggest that IL-12 and rituximab is an active combination and further studies of this combination in B-cell non-Hodgkin lymphoma are warranted. Expand
Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism.
TLDR
The results suggest that Hsp27 up-regulation has a significant role in 17-AAG resistance, which may be mediated in part through GSH regulation, and clinical modulation of GSH may enhance the efficacy of Hsp90-directed therapy. Expand
...
1
2
3
4
5
...